Showing results (1-10 of 258) with videos related to
Sort By:
Pageof 26
Pharmaceutical Statistics|November 3, 2023
Conditional power and information fraction calculations at an interim analysis for random coefficient modelsSandra A Lewis, Kevin J Carroll, Todd DeVries, et al.Pharmaceutical Statistics|April 3, 2024
A practical guide to the appropriate analysis of eGFR data over time: A simulation studyTodd DeVries, Kevin J Carroll, Sandra A LewisNephrology (Carlton, Vic.)|September 27, 2024
Mucosal targeting in IgA nephropathy targeting the gut associated lymphoid tissueJonathan BarrattPharmaceutical Statistics|January 24, 2007
Analysis of progression-free survival in oncology trials: some common statistical issuesKevin J CarrollPharmaceutical Statistics|January 31, 2009
Back to basics: explaining sample size in outcome trials, are statisticians doing a thorough job?Kevin J CarrollJournal of Biopharmaceutical Statistics|August 21, 2013
Decision making from Phase II to Phase III and the probability of success: reassured by "assurance"?Kevin J CarrollControlled Clinical Trials|December 10, 2003
On the use and utility of the Weibull model in the analysis of survival dataKevin J CarrollPharmaceutical Statistics|November 28, 2006
Active-controlled, non-inferiority trials in oncology: arbitrary limits, infeasible sample sizes and uninformative data analysis. is there another way?Kevin J CarrollPharmaceutical Statistics|March 14, 2007
Biomarkers in drug development: friend or foe? A personal reflection gained working within oncologyKevin J CarrollFrontiers in Immunology|September 27, 2021
Complement Factor D as a Strategic Target for Regulating the Alternative Complement PathwayJonathan Barratt, Ilene WeitzPageof 26